Shares of the clinical-stage cancer immunotherapy company Agenus (NASDAQ: AGEN) rose by as much as 46.2% in early-morning trading today on sky-high volume. The spark? Agenus's shares are marching higher today in response to an immuno-oncology collaboration with biotech heavyweight Gilead Sciences (NASDAQ: GILD).
Continue Reading Below
According to the press release, the two companies will develop up to five novel therapies. Since blasting off in the first half of today's trading session, Agenus's shares have cooled off to some degree, but remain up by 30% as of 12:00 p.m. EST.
Apart from the validation this development deal provides for Agenus's checkpoint inhibitor platform, the company will also receive a much-needed infusion of cash. Per the terms of the agreement, Agenus will pocket a healthy $150 million once this deal closes -- $120 million in upfront cash as well as a $30 million equity investment by Gilead.
This sizable upfront cash payment is key because the company ended the most recent quarter with only $46.3 million in cash and cash equivalents, but a quarterly burn rate often exceeding $25 million over the course of 2018.
In the longer term, Agenus could also take home around $1.7 billion in additional milestone payments and associated fees. That's a staggering amount of future milestone payments for a company with a market cap of only $315 million at the time of writing.
By virtue of this deal with Gilead, Agenus has seemingly put to bed two key concerns surrounding its value proposition to investors: the validity of management's decision to pursue a therapeutic area -- anticancer checkpoint inhibitors -- that was arguably already oversaturated with experimental candidates, and the company's exceedingly short cash runway.
With both of these headwinds fading in the wake of this deal, Agenus's risk-to-reward ratio has become far more compelling for investors quite literally overnight. Now, the company still has a lot of work to do to ultimately hit pay dirt, but this Gilead partnership is without question a positive development.
10 stocks we like better than AgenusWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Agenus wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018